BIO Comments on USTR Objectives for U.S. – Japan Trade Agreement
December 12, 2018
BIO welcomes progress made in recent U.S. bilateral trade agreements, in particular with Australia and Korea, to require transparency and accountability of foreign government pricing and reimbursement of biopharmaceuticals, to ensure market access and reward for innovation. BIO believes that to ensure that U.S. trading partners are allowing fair, non-discriminatory access to new medicines, and shouldering a fair share of the costs of innovation, that any modern trade agreement, including a U.S-Japan agreement should build on these provisions.
Download Full Comments Below
BIO Negotiations Objectives - US-Japan Trade Final 112618
Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
BIO welcomes progress made in recent U.S. bilateral trade agreements, in particular with Australia and Korea, to require transparency and accountability of foreign government pricing and reimbursement of biopharmaceuticals, to ensure market access and reward for innovation. BIO believes that to ensure that U.S. trading partners are allowing fair, non-discriminatory access to new medicines, and shouldering a fair share of the costs of innovation, that any modern trade agreement, including a U.S-Japan agreement should build on these provisions.